Trials / Terminated
TerminatedNCT00277836
Study Evaluating MST-997 in Advanced Malignant Solid Tumors
A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MST-997 |
Timeline
- First posted
- 2006-01-16
- Last updated
- 2006-12-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00277836. Inclusion in this directory is not an endorsement.